Nay Nwe Nyein Chan
Associate Research ScientistCards
About
Research
Publications
2025
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.
Trontzas I, He M, Wurtz A, Robbins C, Robinson N, Bates K, Liu M, Aung T, Scott L, Chan N, Burela S, Schillo J, Liebler D, Hill S, Morrison R, Vathiotis I, Syrigos K, Goldberg S, Politi K, Rimm D. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer. Clinical Cancer Research 2025 PMID: 40047548, DOI: 10.1158/1078-0432.ccr-24-3347.Peer-Reviewed Original ResearchNon-small cell lung cancerAntibody-drug conjugatesAntibody-drug conjugate targetsEGFR mutationsCell lung cancerEGFR expressionQuantitative immunofluorescenceWild-type non-small cell lung cancerLung cancerAssociated with EGFR mutationsAssociated with EGFR expressionTissue microarray cohortAssociation of HER2Management of patientsAssay limitProportion of casesMutation statusTROP2 expressionMicroarray cohortEGFRQuantitative protein expressionTreatment sequencePatientsCell linesWild-type270 Pathological Response to Herceptin-containing Neoadjuvant Therapy in HER2 IHC2+/ISH+ and IHC3+ Early-Stage Breast Cancers
Zhan H, Chan N, Rimm D. 270 Pathological Response to Herceptin-containing Neoadjuvant Therapy in HER2 IHC2+/ISH+ and IHC3+ Early-Stage Breast Cancers. Laboratory Investigation 2025, 105: 102494. DOI: 10.1016/j.labinv.2024.102494.Peer-Reviewed Original Research127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer Patients
Chan N, Gaule P, Benanto J, Robbins C, Scott L, Hill S, Morrison R, Liebler D, Fulton R, Rimm D. 127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer Patients. Laboratory Investigation 2025, 105: 102351. DOI: 10.1016/j.labinv.2024.102351.Peer-Reviewed Original Research119 Reading vs Measuring: Comparison of Pathologist-Based Scores to Analytic Measurements
Bates K, Fernandez A, Martinez-Morilla S, Chan N, Benanto J, Reisenbichler E, Rimm D. 119 Reading vs Measuring: Comparison of Pathologist-Based Scores to Analytic Measurements. Laboratory Investigation 2025, 105: 102343. DOI: 10.1016/j.labinv.2024.102343.Peer-Reviewed Original Research
2024
394P Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
Tarantino P, Kim S, Chan N, Hughes M, Smith K, D’Amico O, Kusmick R, Pereslete A, Alder L, Anders C, Morganti S, Garrido-Castro A, Lorusso P, Lustberg M, Sammons S, Lin N, Li T, Tayob N, Rimm D, Tolaney S. 394P Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC). Annals Of Oncology 2024, 35: s384-s385. DOI: 10.1016/j.annonc.2024.08.342.Peer-Reviewed Original ResearchQuantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay
Liu M, Vathiotis I, Robbins C, Chan N, Moutafi M, Burela S, Xirou V, Schalper K, Herbst R, Syrigos K, Rimm D. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay. Modern Pathology 2024, 37: 100556. PMID: 38964502, PMCID: PMC11416319, DOI: 10.1016/j.modpat.2024.100556.Peer-Reviewed Original ResearchNon-small cell lung cancerCases of non-small cell lung cancerNon-small cell lung cancer casesT-DXdCell lung cancerHER2 expressionBreast cancerRare case of non-small cell lung cancerQuantitative immunofluorescenceAntibody-drug conjugate trastuzumab deruxtecanLung cancerHER2 antibody-drug conjugatesNon-small cell lung cancer patientsDetecting HER2 expressionHER2-targeted therapyMetastatic breast cancerHER2 protein expressionBreast cancer casesHER2 protein levelsAntibody-drug conjugatesProportion of casesTrastuzumab deruxtecanNSCLC casesFrequency of casesImmunohistochemistry scoreAbstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
Tarantino P, Hughes M, Kusmick R, Alder L, Pereslete A, Noteware L, Moore H, Van Swearingen A, Li T, Gupta H, Smith K, Morganti S, Files J, Sendrick K, Buck S, Dillon D, Jeselsohn R, Li Y, Cherniack A, Prat A, Chan N, Rimm D, Curigliano G, Sammons S, Anders C, Lin N, Tolaney S. Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE). Cancer Research 2024, 84: ps08-09-ps08-09. DOI: 10.1158/1538-7445.sabcs23-ps08-09.Peer-Reviewed Original ResearchMetastatic breast cancerHER2+ diseaseHER2-lowHER2-low diseaseT-DXdActivity of trastuzumabHER2 statusHER2+Overall survivalHER2-0Breast cancerMetastatic diagnosisPrimary tumorFollow-upHormone receptor (HR)-positive tumorsHistory of brain metastasesHER2-low expressionHER2-low statusHER2-negative casesHER2-negative tumorsMedian follow-upArchival tumor samplesDana-Farber Cancer InstituteInterstitial lung diseaseImpact outcomes
2023
Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Vesely M, Kidacki M, Gaule P, Gupta S, Chan N, Han X, Yeung J, Chen L. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes. Journal Of Investigative Dermatology 2023, 144: 106-115.e4. PMID: 37562584, DOI: 10.1016/j.jid.2023.07.008.Peer-Reviewed Original ResearchConceptsCD11b myeloid cellsImmune inhibitory moleculesPD-L1 expressionVISTA expressionMyeloid cellsFuture potential therapeutic targetsPD-L1/B7Tumor microenvironmentInhibitory moleculesMultiplexed quantitative immunofluorescencePrimary cutaneous melanomaImmunosuppressive tumor microenvironmentNegative prognostic biomarkerCurrent clinical trialsPotential therapeutic targetCause mortalityCritical cell typesPD-L1Poor outcomeTreatment of cancerMelanoma recurrenceCutaneous melanomaClinical trialsPrognostic biomarkerT cells
2022
127 Spatial-specific gene signatures outperform bulk-mRNA signatures to define resistance to immunotherapy in melanoma patients
Aung T, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis L, Chan N, Kluger H, Rimm D. 127 Spatial-specific gene signatures outperform bulk-mRNA signatures to define resistance to immunotherapy in melanoma patients. 2022, a140-a140. DOI: 10.1136/jitc-2022-sitc2022.0127.Peer-Reviewed Original Research
News
News
Get In Touch
Contacts
Email
Mailing Address
Yale School of Medicine
Quantitative Diagnostics in Anatomic Pathology (QDAP) Laboratory , 15 York Street, LMP-B101
NEW HAVEN, CONNECTICUT 06510
United States
Locations
Quantitative Diagnostics in Anatomic Pathology (QDAP) Laboratory
Lab
Laboratory for Medicine and Pediatrics (LMP)
15 York Street, Fl B, Rm 101
New Haven, CT 06510